Immune regulation is critical to health and disease. Immune function is of clear relevance in the setting of hematopoietic cell transplantation and organ transplantation tolerance where controlled immune reactions allows for reduction of graft vs host disease (GVHD) risk and organ acceptance whereas rejection is manifested through GVHD and destruction of the organ graft. Prior work in this program in our laboratory has demonstrated that immune regulatory cells play a major role in control of these immune reactions allowing for the control of GVHD, retention of graft-versus-tumor effects, as well as acceptance of genetically disparate tissue grafts. These studies have been translated to the clinic in a number of different settings including the development of the total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG) regimen pioneered in Project 1 for solid organ transplantation tolerance demonstrating the clear clinical relevance of these strategies to the treatment of patients. In this project, we will dissect the role of two important donor derived regulatory cell populations including CD4+CD25+FoxP3+ regulatory T cells (Treg) and CD1 reactive invariant natural killer T cells (iNK T cells). Prior work in my laboratory has demonstrated that both of these cell populations suppress GVHD across major histocompatibility and minor histocompatibility barriers and that importantly there are specific interactions between these different cell populations. A major challenge has been the paucity of these cell populations for clinical translation. In our proposal, we will build upon recent work using MAbs, fusion protein biologics and natural ligands to study their impact on Treg and iNKT cells and to develop strategies to activate and expand these cell populations. We will further explore important molecules involved in the mechanism of these regulatory cell populations, as well as their interaction with other host myeloid cell populations required for biological function. We will explore the role of these immune regulatory cells following both total body irradiation myeloablative as well as TLI/ATG conditioning to extend and build upon results from the other projects to develop novel insights into immune regulatory mechanisms of action and interactive networks and to develop clinically relevant strategies for translation. Project 2 will explore the underlying biology of these immune regulatory cells, as well as to develop strategies that can be translated to the clinic in current and future clinical trials. This project will interact with Projects 1 and 4 and extensively utilize Cores A and B.

Public Health Relevance

Immune regulation is critical in health and disease. The development of strategies to combine hematopoietic cell transplantation with organ transplantation from the same donor has demonstrated these immune regulatory networks play a critical role in organ acceptance and induction tolerance. In this project we will further explore the underlying biology of immune regulatory cells and how they interact and function. This project has direct relevance to clinical translational studies in the setting of solid organ transplantation tolerance, hematopoietic cell transplantation, the treatment of severe autoimmune diseases and possible other medical disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL075462-14
Application #
9720708
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Welniak, Lisbeth A
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
14
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Kawai, Tatsuo; Leventhal, Joseph; Wood, Kathryn et al. (2018) Summary of the Third International Workshop on Clinical Tolerance. Am J Transplant :
Scandling, John D; Busque, Stephan; Lowsky, Robert et al. (2018) Macrochimerism and clinical transplant tolerance. Hum Immunol 79:266-271
Simonetta, Federico; Alvarez, Maite; Negrin, Robert S (2017) Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol 8:465
Zhang, Hong; Gregorio, Josh D; Iwahori, Toru et al. (2017) A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes. Proc Natl Acad Sci U S A 114:1988-1993
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Pierini, Antonio; Nishikii, Hidekazu; Baker, Jeanette et al. (2017) Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun 8:15068
Mavers, Melissa; Maas-Bauer, Kristina; Negrin, Robert S (2017) Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 8:900
Hongo, David; Tang, Xiaobin; Zhang, Xiangyue et al. (2017) Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood 129:1718-1728
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Revelo, Xavier S; Ghazarian, Magar; Chng, Melissa Hui Yen et al. (2016) Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance. Cell Rep 16:717-30

Showing the most recent 10 out of 70 publications